FAQ

BRM270

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2015-2017
01220152017

Related topics

Related topics

1 relation

Broader (1)

Jiedu Xiaozheng Yin

Related mentions per year

Related mentions per year

1990-2018
1990200020102020
BRM270
Jiedu Xiaozheng Yin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BRM270 inhibits cancer stem cell maintenance via microRNA regulation in chemoresistant A549 lung adenocarcinoma cells
Chemotherapy is a standard treatment for non-small-cell lung cancer (NSCLC). However, the dose-limiting toxicity of drugs and the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
Novel phyto-derivative BRM270 inhibits hepatocellular carcinoma cells proliferation by inducing G2/M phase cell cycle arrest and apoptosis in xenograft mice model.
Hepatocellular carcinoma (HCC) is a major threat to human health worldwide and development of novel antineoplastic drug is… (More)
Is this relevant?
2017
2017
BRM270, a Compound from Natural Plant Extracts, Inhibits Glioblastoma Stem Cell Properties and Glioblastoma Recurrence.
Glioblastoma multiforme (GBM) is one of the most aggressive and lethal human brain tumors, and the median survival of patients… (More)
Is this relevant?
2016
2016
Epigenetic induction of epithelial to mesenchymal transition by LCN2 mediates metastasis and tumorigenesis, which is abrogated by NF-κB inhibitor BRM270 in a xenograft model of lung adenocarcinoma
Tumor initiating cancer stem-like cells (TICSCs) have recently become the object of intensive study. Human-Lipocalin-2 (hLCN2… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
The novel inhibitor BRM270 downregulates tumorigenesis by suppression of NF-κB signaling cascade in MDR-induced stem like cancer-initiating cells.
The nuclear factor κB (NF-κB) and interleukin-6 (IL-6) contribute to multidrug resistance (MDR) in tumor chemotherapy. The… (More)
  • table I
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?